^
Association details:
| Biomarker: | CEBPA mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vyxeos (cytarabine/daunorubicin liposomal formulation) (DNA synthesis inhibitor, Topoisomerase II inhibitor, DNA polymerase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia
Published date:
11/01/2018
Excerpt:
We retrospectively analyzed a combined cohort of 111 pts treated with CPX-351 from Moffitt Cancer Center...High RR (>70%) were also observed in pts with rare mutations such as STAG2 (n=6), SF3B1 (n=6), PHF6 (n=6) or biallelic CEBPA (n=3).
DOI:
10.1182/blood-2018-99-117412
